X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (294) 294
Book Review (96) 96
Publication (15) 15
Magazine Article (8) 8
Newsletter (6) 6
Book Chapter (3) 3
Conference Proceeding (2) 2
Trade Publication Article (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (214) 214
humans (194) 194
pegaptanib (194) 194
ranibizumab (161) 161
ophthalmology (160) 160
macular degeneration (133) 133
bevacizumab (124) 124
pegaptanib sodium (120) 120
vascular endothelial growth factor a - antagonists & inhibitors (116) 116
vascular endothelial growth factor (91) 91
aptamers, nucleotide - therapeutic use (79) 79
endothelial growth-factor (75) 75
age-related macular degeneration (73) 73
female (72) 72
male (72) 72
angiogenesis inhibitors - therapeutic use (71) 71
macular degeneration - drug therapy (66) 66
aged (65) 65
photodynamic therapy (60) 60
choroidal neovascularization (57) 57
choroidal neovascularization - drug therapy (52) 52
treatment outcome (49) 49
eye diseases (48) 48
intravitreal injections (48) 48
antibodies, monoclonal, humanized (47) 47
middle aged (43) 43
animals (40) 40
pharmacology & pharmacy (39) 39
visual acuity (39) 39
neovascularization (38) 38
aged, 80 and over (37) 37
care and treatment (37) 37
physiological aspects (37) 37
verteporfin (37) 37
aptamers, nucleotide - administration & dosage (36) 36
angiogenesis inhibitors - administration & dosage (35) 35
genetic structures (35) 35
diabetic retinopathy (34) 34
diabetic macular edema (32) 32
drug therapy (32) 32
visual acuity - physiology (32) 32
angiogenesis inhibitors - adverse effects (31) 31
fluorescein angiography (31) 31
medicine & public health (31) 31
research (31) 31
anti-vegf (30) 30
aptamers, nucleotide - adverse effects (30) 30
macular degeneration - complications (30) 30
vegf (30) 30
antibodies, monoclonal - therapeutic use (29) 29
therapy (29) 29
vitreous body (29) 29
tomography, optical coherence (28) 28
angiogenesis (27) 27
dosage and administration (27) 27
injections (27) 27
triamcinolone (27) 27
analysis (26) 26
choroidal neovascularization - etiology (26) 26
intravitreal bevacizumab (26) 26
retrospective studies (26) 26
injection (25) 25
intravitreal bevacizumab avastin (25) 25
macular degeneration - physiopathology (25) 25
bevacizumab avastin (24) 24
macular edema - drug therapy (24) 24
safety (24) 24
sense organs (24) 24
visual acuity - drug effects (23) 23
clinical trials (22) 22
intravitreal injection (22) 22
subfoveal choroidal neovascularization (22) 22
antibodies, monoclonal, humanized - therapeutic use (21) 21
laser photocoagulation (21) 21
prospective studies (21) 21
choroidal neovascularization - physiopathology (20) 20
degeneration (20) 20
aflibercept (19) 19
diabetic retinopathy - drug therapy (19) 19
optical coherence tomography (19) 19
verteporfin photodynamic therapy (19) 19
wet macular degeneration - drug therapy (19) 19
antibodies, monoclonal - administration & dosage (18) 18
diabetes (18) 18
edema (18) 18
review (18) 18
studies (18) 18
triamcinolone acetonide (18) 18
aptamer (17) 17
glaucoma (17) 17
photochemotherapy (17) 17
medicine, research & experimental (16) 16
retina (16) 16
antibodies, monoclonal - adverse effects (15) 15
cancer (15) 15
drug therapy, combination (15) 15
follow-up studies (15) 15
macugen (15) 15
macular edema (15) 15
randomized controlled trials as topic (15) 15
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (288) 288
French (6) 6
German (6) 6
Turkish (4) 4
Polish (3) 3
Czech (2) 2
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Ophthalmology, ISSN 1177-5467, 02/2015, Volume 9, pp. 323 - 335
Population pharmacokinetic modeling of pegaptanib was undertaken to determine influence of renal function on apparent clearance. In a randomized, double-masked... 
Population pharmacokinetics | Renal function | Clearance | Pegaptanib | Diabetic macular edema | Diabetic retinopathy | Patient outcomes | Drug metabolism | Eye diseases | Drug therapy | Observations | Macular degeneration | Studies | Edema | Sodium | Population | Diabetes | Permeability | Vascular endothelial growth factor | Drug dosages | Age | Creatinine | Extrapolation | Dosing | Mathematical models | Exposure | Clearances | Patients
Journal Article
Acta Ophthalmologica, ISSN 1755-375X, 09/2009, Volume 87, Issue 6, pp. 623 - 630
Journal Article
Retina, ISSN 0275-004X, 02/2013, Volume 33, Issue 2, pp. 397 - 402
Journal Article
Journal Article
Experimental and Therapeutic Medicine, ISSN 1792-0981, 12/2017, Volume 14, Issue 6, pp. 6002 - 6006
The aim of the present study was to report the importance of pegaptanib sodium (PGSD) injection treatment for vascular active vitreoretinopathy (VAVR). A total... 
Vascular active vitreoretinopathy | Visual acuity | Inflammation | Pegaptanib sodium | SURGERY | MEDICINE, RESEARCH & EXPERIMENTAL | vascular active vitreoretinopathy | visual acuity | MACUGEN | MACULAR DEGENERATION | pegaptanib sodium | LOCUS | TRACTION | THERAPY | inflammation | DISEASE | PROLIFERATIVE VITREORETINOPATHY | FAMILIAL EXUDATIVE VITREORETINOPATHY
Journal Article
Japanese Journal of Ophthalmology, ISSN 0021-5155, 9/2013, Volume 57, Issue 5, pp. 417 - 423
Journal Article
British Journal of Ophthalmology, ISSN 0007-1161, 12/2010, Volume 94, Issue 12, p. 1611
Journal Article